Anavex Life Sciences Corp. (0HFR.L)
USD 9.08
(-3.55%)
USD 9.08
(-3.55%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -47.5 Million USD | 1.01% |
| 2022 | -47.97 Million USD | -26.56% |
| 2021 | -37.9 Million USD | -44.25% |
| 2020 | -26.28 Million USD | 0.06% |
| 2019 | -26.29 Million USD | -50.66% |
| 2018 | -17.45 Million USD | -29.66% |
| 2017 | -13.46 Million USD | 8.66% |
| 2016 | -14.73 Million USD | -21.71% |
| 2015 | -12.1 Million USD | -6.51% |
| 2014 | -11.36 Million USD | -207.25% |
| 2013 | -3.7 Million USD | 55.43% |
| 2012 | -8.3 Million USD | -13.61% |
| 2011 | -7.3 Million USD | 16.8% |
| 2010 | -8.78 Million USD | -59.71% |
| 2009 | -5.49 Million USD | -2.77% |
| 2008 | -5.35 Million USD | -238.69% |
| 2007 | -1.57 Million USD | -6088.29% |
| 2006 | -25.53 Thousand USD | 72.13% |
| 2005 | -91.62 Thousand USD | -536.51% |
| 2004 | -14.39 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -10.54 Million USD | -22.32% |
| 2024 Q1 | -8.62 Million USD | 15.02% |
| 2024 Q3 | -12.21 Million USD | -15.82% |
| 2023 Q3 | -11.27 Million USD | 13.94% |
| 2023 FY | -47.49 Million USD | 1.01% |
| 2023 Q2 | -13.1 Million USD | -1.05% |
| 2023 Q1 | -12.97 Million USD | 9.23% |
| 2023 Q4 | -10.14 Million USD | 10.05% |
| 2022 Q3 | -12.36 Million USD | -18.49% |
| 2022 Q1 | -10.88 Million USD | 7.13% |
| 2022 FY | -47.97 Million USD | -26.56% |
| 2022 Q4 | -14.29 Million USD | -15.55% |
| 2022 Q2 | -10.43 Million USD | 4.09% |
| 2021 Q3 | -10.18 Million USD | -24.83% |
| 2021 Q4 | -11.71 Million USD | -15.11% |
| 2021 FY | -37.9 Million USD | -44.25% |
| 2021 Q1 | -7.85 Million USD | -31.68% |
| 2021 Q2 | -8.15 Million USD | -3.82% |
| 2020 Q2 | -7.23 Million USD | -9.78% |
| 2020 FY | -26.28 Million USD | 0.06% |
| 2020 Q3 | -6.48 Million USD | 10.36% |
| 2020 Q4 | -5.96 Million USD | 8.04% |
| 2020 Q1 | -6.59 Million USD | -69.92% |
| 2019 Q2 | -8 Million USD | -9.2% |
| 2019 FY | -26.29 Million USD | -50.66% |
| 2019 Q1 | -7.33 Million USD | -26.59% |
| 2019 Q3 | -7.07 Million USD | 11.66% |
| 2019 Q4 | -3.87 Million USD | 45.16% |
| 2018 Q4 | -5.79 Million USD | -103.32% |
| 2018 Q3 | -2.84 Million USD | 40.04% |
| 2018 FY | -17.45 Million USD | -29.66% |
| 2018 Q1 | -4.05 Million USD | 21.25% |
| 2018 Q2 | -4.75 Million USD | -17.07% |
| 2017 Q1 | -3.14 Million USD | 51.67% |
| 2017 FY | -13.46 Million USD | 8.66% |
| 2017 Q3 | -3.61 Million USD | -133.05% |
| 2017 Q2 | -1.54 Million USD | 50.77% |
| 2017 Q4 | -5.15 Million USD | -42.78% |
| 2016 Q4 | -6.51 Million USD | -190.62% |
| 2016 Q1 | -3.95 Million USD | 26.17% |
| 2016 FY | -14.73 Million USD | -21.71% |
| 2016 Q2 | -2.03 Million USD | 48.65% |
| 2016 Q3 | -2.24 Million USD | -10.32% |
| 2015 FY | -12.1 Million USD | -6.51% |
| 2015 Q4 | -5.35 Million USD | -26.32% |
| 2015 Q3 | -4.24 Million USD | -145.83% |
| 2015 Q2 | -1.72 Million USD | -119.25% |
| 2015 Q1 | -786.71 Thousand USD | 91.89% |
| 2014 Q4 | -9.69 Million USD | -861.17% |
| 2014 Q3 | -1 Million USD | 0.96% |
| 2014 Q2 | -1.01 Million USD | -384.09% |
| 2014 FY | -11.36 Million USD | -207.25% |
| 2014 Q1 | 358.63 Thousand USD | 112.0% |
| 2013 Q1 | -453.51 Thousand USD | 33.05% |
| 2013 FY | -3.7 Million USD | 55.43% |
| 2013 Q4 | -2.98 Million USD | -1867.11% |
| 2013 Q2 | -106.1 Thousand USD | 76.61% |
| 2013 Q3 | -151.92 Thousand USD | -43.19% |
| 2012 Q3 | -4.54 Million USD | -399.08% |
| 2012 Q4 | -677.38 Thousand USD | 85.09% |
| 2012 FY | -8.3 Million USD | -13.61% |
| 2012 Q2 | -910.2 Thousand USD | 58.15% |
| 2012 Q1 | -2.17 Million USD | -53.0% |
| 2011 Q3 | -1.57 Million USD | 19.95% |
| 2011 Q1 | -1.88 Million USD | 32.39% |
| 2011 FY | -7.3 Million USD | 16.8% |
| 2011 Q4 | -1.42 Million USD | 9.98% |
| 2011 Q2 | -1.97 Million USD | -4.54% |
| 2010 FY | -8.78 Million USD | -59.71% |
| 2010 Q4 | -2.79 Million USD | -41.97% |
| 2010 Q3 | -1.96 Million USD | -14.68% |
| 2010 Q2 | -1.71 Million USD | -282.19% |
| 2010 Q1 | -448.5 Thousand USD | 77.47% |
| 2009 Q1 | -928.04 Thousand USD | 55.2% |
| 2009 Q2 | -1.24 Million USD | -33.76% |
| 2009 Q3 | -1.33 Million USD | -7.92% |
| 2009 Q4 | -1.99 Million USD | -48.57% |
| 2009 FY | -5.49 Million USD | -2.77% |
| 2008 Q3 | -1.68 Million USD | -146.38% |
| 2008 Q2 | -682 Thousand USD | 25.65% |
| 2008 FY | -5.35 Million USD | -238.69% |
| 2008 Q1 | -917.3 Thousand USD | 19.8% |
| 2008 Q4 | -2.07 Million USD | -23.29% |
| 2007 Q3 | -254.84 Thousand USD | -50.7% |
| 2007 FY | -1.57 Million USD | -6088.29% |
| 2007 Q2 | -169.1 Thousand USD | -1275.39% |
| 2007 Q4 | -1.14 Million USD | -348.8% |
| 2007 Q1 | -12.29 Thousand USD | -113.64% |
| 2006 Q3 | -5680.00 USD | -21.89% |
| 2006 Q4 | -5755.00 USD | -1.32% |
| 2006 FY | -25.53 Thousand USD | 72.13% |
| 2006 Q1 | -9437.00 USD | 77.54% |
| 2006 Q2 | -4660.00 USD | 50.62% |
| 2005 FY | -91.62 Thousand USD | -536.51% |
| 2005 Q3 | -45.69 Thousand USD | 0.0% |
| 2005 Q2 | -45.69 Thousand USD | -1071.14% |
| 2005 Q4 | -42.02 Thousand USD | 8.04% |
| 2005 Q1 | -3902.00 USD | 0.0% |
| 2004 FY | -14.39 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | 68.995% |
| Dynavax Technologies Corporation | -6.38 Million USD | -643.544% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 3709.802% |
| Perrigo Company plc | -12.7 Million USD | -274.055% |
| Illumina, Inc. | -1.16 Billion USD | 95.908% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 100.792% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 89.302% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 99.45% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 103.498% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 57.032% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 101.202% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -19.18% |
| Waters Corporation | 642.23 Million USD | 107.397% |
| Biogen Inc. | 1.16 Billion USD | 104.091% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 81.575% |
| Evolus, Inc. | -61.68 Million USD | 22.988% |
| Adicet Bio, Inc. | -142.65 Million USD | 66.7% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 59.916% |
| bluebird bio, Inc. | -211.91 Million USD | 77.583% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 77.297% |
| FibroGen, Inc. | -284.23 Million USD | 83.287% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 103.831% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -6.506% |
| Homology Medicines, Inc. | -53.74 Million USD | 11.607% |
| Geron Corporation | -184.12 Million USD | 74.2% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 89.209% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 68.661% |
| Myriad Genetics, Inc. | -112 Million USD | 57.585% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 44.694% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 90.128% |
| Zoetis Inc. | 2.34 Billion USD | 102.027% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 12.333% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 106.023% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 128.337% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 101.312% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -12.574% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 87.031% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 82.796% |
| Verastem, Inc. | -87.36 Million USD | 45.626% |
| Nektar Therapeutics | -276.05 Million USD | 82.792% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 80.143% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 46.311% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 91.137% |
| OPKO Health, Inc. | -188.86 Million USD | 74.847% |
| Exelixis, Inc. | 207.76 Million USD | 122.865% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 119.025% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 144.757% |
| uniQure N.V. | -308.47 Million USD | 84.6% |
| Imunon, Inc. | -19.51 Million USD | -143.428% |
| Blueprint Medicines Corporation | -506.98 Million USD | 90.63% |
| Insmed Incorporated | -749.56 Million USD | 93.662% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 116.87% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 86.508% |
| TG Therapeutics, Inc. | 12.67 Million USD | 474.882% |
| Incyte Corporation | 597.59 Million USD | 107.949% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 93.753% |